The Standard Dose of Mounjaro — and Why There Isn't Just One

The misconception: 15 mg is 'the' Mounjaro dose you should aim for

A common assumption, understandable given how the trial results are reported, is that 15 mg is what Mounjaro is supposed to be, and that anything lower is somehow a lesser version of the treatment. The SURMOUNT-1 data does come from the 15 mg arm, where average weight reduction reached around 20–21% over 72 weeks, as published in the New England Journal of Medicine. But that was a controlled trial in which participants were titrated systematically to 15 mg. Real clinical practice looks different.

Prescribers aim for the lowest dose at which you achieve meaningful, sustained results without intolerable side effects. For some people that's 7.5 mg. For others it's 10 mg. Chasing 15 mg when a lower dose is already working is not clinically indicated, and pushing through side effects to get there faster is actively counterproductive. The titration schedule exists precisely to prevent that.

So if you're reading about the standard Mounjaro dose because you're wondering whether your current dose is the right one, the honest answer is: your prescriber should be making that call, not a search result.

What the six UK strengths are actually for

The six licensed UK strengths (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg) map onto a progressive titration ladder. Each step is spaced roughly four weeks apart to give your gastrointestinal system time to settle before the next increase. The NHS tirzepatide page confirms this structure and sets out the side effects most associated with dose changes.

The 2.5 mg pen is the starting pen. Its purpose is adjustment, not appetite suppression. Most people do not notice dramatic changes at this stage, and that is expected. The 5 mg step is often where appetite reduction begins to feel meaningful, and if you want to understand what the Mounjaro 5 mg dose involves, you can read more about that experience on the 5 mg overview page. Steps above that are about finding the dose at which weight loss stabilises at a clinically useful rate.

Not everyone needs to go beyond 7.5 mg or 10 mg, and there is no clinical requirement to reach 15 mg. The SmPC and your prescriber's clinical judgement are the two authorities on when to increase and when to hold. Titration timing and missed doses are questions for your prescriber and the Patient Information Leaflet, not something a content page should prescribe.

How dose decisions work in practice at a regulated pharmacy

At a GPhC-registered pharmacy like nume, every repeat order is clinically re-reviewed before anything is dispensed. That means a prescriber looks at your reported experience at the current dose (side effects, appetite response, any changes to your health) before confirming whether the next strength is appropriate. Evidence of current treatment and current weight is required for dose increases; this is not an automatic process.

When a pen does arrive, it comes via tracked DPD delivery in plain, unbranded packaging: nothing on the outside to suggest what's inside. The pen itself is the Mounjaro KwikPen, a pre-filled device that delivers four once-weekly doses at the stated strength. Knowing which strength you're holding matters, because there is no visible difference in the size or shape of the pens across the dose range. If you have questions about what the volume per dose looks like, that page goes into more detail.

For anyone wondering about cost in the context of dose titration, the Mounjaro cost guide explains how pricing relates to strength and what a legitimate prescription actually includes. The short version: what you pay should cover clinical review, not just the pen.

Who can be prescribed Mounjaro, and what eligibility actually means

Mounjaro holds a UK licence for weight management in adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related condition, high blood pressure, high cholesterol, obstructive sleep apnoea, cardiovascular disease or type 2 diabetes are among those relevant conditions. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. NICE's appraisal of tirzepatide (TA1026) sets out the recommendation criteria in full.

A BMI that meets the threshold does not guarantee a prescription. A prescriber reviews the complete picture: your medical history, current medications, contraindications and whether there are clinical reasons to proceed cautiously or not at all. People who are pregnant, breastfeeding or trying to conceive are not suitable candidates. Those under 18 fall outside the licensed indication. A history of certain conditions (including medullary thyroid carcinoma or pancreatitis) requires careful discussion before any GLP-1 medicine is considered.

The Mounjaro overview covers eligibility in more depth, including the NHS access criteria, which differ from private licensed eligibility. If you want to explore whether treatment is right for your situation, the place to start is a clinical consultation, not a dose comparison table. Check your eligibility and speak to our prescribers through the weight-loss treatments page.